{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:39:02Z","timestamp":1787841542871,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","award":["Eli Lilly Japan"],"award-info":[{"award-number":["Eli Lilly Japan"]}],"id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01889-6","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:54:32Z","timestamp":1783346072000},"page":"1138-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0135-5001","authenticated-orcid":false,"given":"Kazutaka","family":"Narui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Miyahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimitsu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kitada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Kikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1889_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12282-025-01671-0","volume":"32","author":"M Nagahashi","year":"2025","unstructured":"Nagahashi M, Kumamaru H, Kinukawa N, Iwamoto T, Kawashima M, Kinoshita T, et al. Breast cancer statistics for Japan in 2022: annual report of the national clinical database-breast cancer registry\u2014clinical implications including chemosensitivity of breast cancer with low estrogen receptor expression. Breast Cancer. 2025;32:217\u201326. https:\/\/doi.org\/10.1007\/s12282-025-01671-0.","journal-title":"Breast Cancer"},{"key":"1889_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"key":"1889_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(15)00613-0.","journal-title":"Lancet Oncol"},{"key":"1889_CR4","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2013 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"key":"1889_CR5","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"key":"1889_CR6","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"1889_CR7","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"key":"1889_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"key":"1889_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr., Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2020;6:116\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782.","journal-title":"JAMA Oncol"},{"key":"1889_CR10","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMc2004229","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Jerusalem G. Ribociclib plus fulvestrant in advanced breast cancer. Reply. N Engl J Med. 2020;382:e85. https:\/\/doi.org\/10.1056\/NEJMc2004229.","journal-title":"N Engl J Med"},{"key":"1889_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"SA Im","year":"2019","unstructured":"Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"key":"1889_CR12","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","volume":"23","author":"MN Dickler","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(\u2013) metastatic breast cancer. Clin Cancer Res. 2017;23:5218\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0754.","journal-title":"Clin Cancer Res"},{"key":"1889_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejca.2016.09.019","volume":"69","author":"S Sutherland","year":"2016","unstructured":"Sutherland S, Miles D, Makris A. Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. Eur J Cancer. 2016;69:216\u201322. https:\/\/doi.org\/10.1016\/j.ejca.2016.09.019.","journal-title":"Eur J Cancer"},{"key":"1889_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(22)00196-6","volume":"23","author":"S Saji","year":"2022","unstructured":"Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:636\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(22)00196-6.","journal-title":"Lancet Oncol"},{"key":"1889_CR15","doi-asserted-by":"publisher","first-page":"103575","DOI":"10.1016\/j.breast.2023.08.007","volume":"72","author":"T Decker","year":"2023","unstructured":"Decker T, Ludtke-Heckenkamp K, Melnichuk L, Hirmas N, Lubbe K, Zahn MO, et al. Anti-hormonal maintenance treatment with the CDK4\/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive \/ HER2 negative metastatic breast cancer: a phase II trial (AMICA). Breast. 2023;72:103575. https:\/\/doi.org\/10.1016\/j.breast.2023.08.007.","journal-title":"Breast"},{"key":"1889_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12282-025-01680-z","volume":"32","author":"S Nakayama","year":"2025","unstructured":"Nakayama S, Iwamoto T, Araki K, Narui K, Nakayama T, Nagase H, et al. A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy. Breast Cancer. 2025;32:607\u201312. https:\/\/doi.org\/10.1007\/s12282-025-01680-z.","journal-title":"Breast Cancer"},{"key":"1889_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10549-019-05134-x","volume":"174","author":"NML Battisti","year":"2019","unstructured":"Battisti NML, Kingston B, King J, Denton A, Waters S, Sita-Lumsden A, et al. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Res Treat. 2019;174:731\u201340. https:\/\/doi.org\/10.1007\/s10549-019-05134-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1889_CR18","doi-asserted-by":"publisher","unstructured":"Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, et al. nextMONARCH: abemaciclib monotherapy or combined with tamoxifen for metastatic breast cancer. Clin Breast Cancer. 2021;21. https:\/\/doi.org\/10.1016\/j.clbc.2020.09.011. :181\u2009\u2013\u200990 e2.","DOI":"10.1016\/j.clbc.2020.09.011"},{"key":"1889_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-022-06662-9","volume":"195","author":"E Hamilton","year":"2022","unstructured":"Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, et al. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2- metastatic breast cancer. Breast Cancer Res Treat. 2022;195:55\u201364. https:\/\/doi.org\/10.1007\/s10549-022-06662-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1889_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43:1101\u201312. https:\/\/doi.org\/10.1200\/JCO-24-02086.","journal-title":"J Clin Oncol"},{"key":"1889_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2410858.","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01889-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01889-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:04Z","timestamp":1787839144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01889-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1889"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01889-6","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with the Declaration of Helsinki and the Ethical Guidelines for Clinical Research of the Ministry of Health, Labour and Welfare of Japan. The study protocol (UMIN 000037395) was approved by the Institutional Review Board of Yokohama City University on 28 November 2019 (approval number: B191000019) and subsequently by all participating institutions.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KN reports honoraria for lectures from Eli Lilly, Daiichi-Sankyo, AstraZeneca, and Chugai. AY reports honoraria for lectures from AstraZeneca, Daiichi-Sankyo, Eli Lilly, Medicon, Pfizer, Taiho, Gilead, Chugai, Eisai, Kyowa Kirin, MSD, Takeda, and Exact Science. TN reports honoraria for lectures from Chugai, Eli Lilly, Novartis, AstraZeneca, Pfizer, Taiho, Daiichi-Sankyo, Eisai, MSD, Sandoz, Celltrion, Yakult, and Nippon Kayaku. TIs reports honoraria for lectures from AstraZeneca, Daiichi-Sankyo, Chugai, Eisai, Pfizer, and MSD. NT reports honoraria for lectures from Eisai, Pfizer, Chugai, Daiichi-Sankyo, Eli Lilly, Kyowa Kirin, AstraZeneca, MSD, Takeda, and Boehringer Ingelheim. YK reports honoraria from Eisai, Daiichi-Sankyo, Eli Lilly, Chugai, AstraZeneca, Pfizer, and MSD. HM reports honoraria from Takeda and Taiho. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}